| November 16, 2010 |
November 16, 2010
Cerus' INTERCEPT Blood System for Plasma Receives Swiss Approval
|
| November 12, 2010 |
November 12, 2010
Cerus to Present at the Stephens Fall Investment Conference
|
| November 12, 2010 |
November 12, 2010
Cerus to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
|
| November 10, 2010 |
November 10, 2010
Cerus Corporation Prices Public Offering of Common Stock and Warrants
|
| November 3, 2010 |
November 3, 2010
Cerus Awarded $489,000 Under U.S. Qualified Therapeutic Discovery Project Program
|
| October 28, 2010 |
October 28, 2010
Cerus Corporation Reports Third Quarter Results
|
| October 12, 2010 |
October 12, 2010
CSL Limited and Cerus Corporation Enter Distribution Agreement for the INTERCEPT Blood System in Australia and New Zealand
|
| October 6, 2010 |
October 6, 2010
Cerus to Release Third Quarter Results on October 28, 2010
|
| September 27, 2010 |
September 27, 2010
Cerus' INTERCEPT Platelet System Succeeds in 3-Year French Study
|
| September 23, 2010 |
September 23, 2010
Cerus Awarded $1.4 Million to Advance Development of Pathogen Inactivation for Red Blood Cells
|
| September 8, 2010 |
September 8, 2010
Cerus to Present at the Robert W. Baird 2010 Health Care Conference
|
| September 7, 2010 |
September 7, 2010
Whittemore Peterson Institute and Cerus Announce Inactivation of XMRV in Platelets and Red Blood Cells by the INTERCEPT Blood System
|
| September 2, 2010 |
September 2, 2010
Cerus and the Swiss Red Cross Report Successful Outcome of INTERCEPT Blood System Platelet Study
|
| August 24, 2010 |
August 24, 2010
Cerus Signs Agreement to Acquire INTERCEPT Blood System Asian Commercial Rights from BioOne
|
| July 29, 2010 |
July 29, 2010
Cerus Corporation Reports Second Quarter Revenues
|
| July 12, 2010 |
July 12, 2010
Cerus to Release Second Quarter Results on July 29, 2010
|
| June 30, 2010 |
June 30, 2010
Study Results Presented at International Transfusion Congress Highlight Cerus' Progress Toward Improving the Safety of Platelets, Plasma and Red Blood Cells
|
| May 19, 2010 |
May 19, 2010
Cerus Appoints William "Obi" Greenman as Chief Business Officer
|
| May 18, 2010 |
May 18, 2010
Whittemore Peterson Institute and Cerus Confirm Inactivation of XMRV by the INTERCEPT Blood System
|
| April 29, 2010 |
April 29, 2010
Cerus Corporation Announces First Quarter 2010 Financial Results
|
| April 7, 2010 |
April 7, 2010
Cerus to Release First Quarter Results on April 29, 2010
|
| April 6, 2010 |
April 6, 2010
Cerus and Oxford Finance Corporation Enter into $10 Million Growth Capital Credit Facility
|
| March 31, 2010 |
March 31, 2010
Cerus Signs Agreement with Swiss Red Cross for Deployment of the INTERCEPT Blood System for Platelets
|
| March 2, 2010 |
March 2, 2010
Cerus to Present at Cowen and Company Annual Health Care Conference
|
| February 23, 2010 |
February 23, 2010
Cerus Announces Fourth Quarter and Year-End 2009 Results
|
| February 17, 2010 |
February 17, 2010
Data Presented at International Haemovigilance Seminar Confirm Safety of Cerus' INTERCEPT Blood System for Platelets and Plasma
|
| February 9, 2010 |
February 9, 2010
Cerus to Collaborate with French National Transfusion Service on INTERCEPT Red Blood Cell Development
|
| February 8, 2010 |
February 8, 2010
Cerus Corporation Reports Positive Outcome of Phase 1 Clinical Trial of INTERCEPT Red Blood Cells
|
| February 4, 2010 |
February 4, 2010
Cerus to Release Fourth Quarter and Year-End 2009 Results on February 23, 2010
|
| February 2, 2010 |
February 2, 2010
Cerus to Present at 12th Annual BIO CEO & Investor Conference
|
| January 14, 2010 |
January 14, 2010
Cerus Corporation Reports Positive Outcome in European Study of 7-Day INTERCEPT Platelets
|